OPT-821
Showing 1 - 25 of 246
Neuroblastoma Trial in New York (dietary supplement, drug, biological)
Recruiting
- Neuroblastoma
- β-glucan
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Dec 5, 2022
Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma Trial in United States (OPT-821 (QS-21), oral ß-glucan)
Recruiting
- Neuroblastoma
- +2 more
- OPT-821 (QS-21)
- oral β-glucan
-
Basking Ridge, New Jersey
- +6 more
Sep 21, 2023
Neuroblastoma Trial in New York (adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH,
Active, not recruiting
- Neuroblastoma
- adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH
- oral β-glucan
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Oct 11, 2021
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer Trial (immunological adjuvant OPT-821, polyvalent
Withdrawn
- Fallopian Tube Cancer
- +2 more
- immunological adjuvant OPT-821
- polyvalent antigen-KLH conjugate vaccine
- (no location specified)
Feb 20, 2020
Metastatic Breast Cancer Trial in Worldwide (OPT-822/OPT-821(30 µg/100 µg), Phosphate Buffer Saline (PBS), Cyclophosphamide)
Completed
- Metastatic Breast Cancer
- OPT-822/OPT-821(30 μg/100 μg)
- +2 more
-
Birmingham, Alabama
- +42 more
Sep 14, 2020
Fallopian Tubes Cancer, Ovarian Cancer, Peritoneal Cancer Trial in New York (bevacizumab and the polyvalent vaccine-KLH
Completed
- Fallopian Tubes Cancer
- +2 more
- bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
-
New York, New YorkMemorial Sloan-Kettering Cancer Center
May 14, 2018
Esophageal Cancer Trial (OBI-833/OBI-821)
Recruiting
- Esophageal Cancer
- OBI-833/OBI-821
-
Taipei, TaiwanNational Taiwan University Hospital
Sep 22, 2022
HIV, Men, Treatment Adherence Trial in East London, Cape Town (U=U testing messaging scripts, U=U adherence messaging scripts)
Not yet recruiting
- HIV Infections
- +2 more
- U=U testing messaging scripts
- U=U adherence messaging scripts
-
East London, Eastern Cape, South Africa
- +1 more
Oct 27, 2022
Peripheral Artery Disease Trial in Philadelphia (Opt-out)
Recruiting
- Peripheral Artery Disease
- Opt-out
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania
Oct 12, 2022
Triple Negative Breast Cancer Trial in Worldwide (biological, device, other)
Recruiting
- Triple Negative Breast Cancer
- adagloxad simolenin combined with OBI-821
- +2 more
-
Harbor City, California
- +97 more
Jul 5, 2022
Screen to Prevent: Using Digital Health to Improve HIV Screening
Not yet recruiting
- HIV Infections
- Universal Opt-out HIV Screening
-
Columbus, Ohio
- +3 more
Aug 21, 2023
IVF Trial in Udaipur (OPTIVF dosage, traditional Dosage)
Recruiting
- IVF
- OPTIVF dosage
- traditional Dosage
-
Udaipur, Rajsthan, IndiaIndira IVF
Aug 7, 2023
IVF Trial in Mumbai (OPTIVF dosage, traditional drug treament)
Recruiting
- IVF
- OPTIVF dosage
- traditional drug treament
-
Mumbai, Maharashtra, IndiaIndira IVF
Mar 30, 2023
Age-Related Macular Degeneration, Retinitis Pigmentosa, Ultrasound Therapy; Complications Trial (Non-invasive ultrasound retinal
Not yet recruiting
- Age-Related Macular Degeneration
- +2 more
- Non-invasive ultrasound retinal stimulation Device
- (no location specified)
Jun 19, 2023
Labor, Induced, Patient Preference Trial in Tampa, Columbus (Elective Induction of Labor Decision Support Tool)
Recruiting
- Labor, Induced
- Patient Preference
- Elective Induction of Labor Decision Support Tool
-
Tampa, Florida
- +1 more
Apr 20, 2023
Ovarian Epithelial Cancer, Carcinoma in Situ, Ovarian Cancer Trial in Worldwide (Lavage of the Cavum uteri and proximal
Completed
- Ovarian Epithelial Cancer
- +2 more
- Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
-
Graz, Austria
- +13 more
Sep 1, 2022
Optimizing Vancomycin Therapy in Children
Recruiting
- Sepsis
- +3 more
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Jan 17, 2023
Hepatitis C Trial in Denver, Baltimore, Jackson (HCV Screening)
Enrolling by invitation
- Hepatitis C
- HCV Screening
-
Denver, Colorado
- +2 more
Feb 25, 2022
NSCLC Trial (30 µg OBI-833/100 µg OBI-821, Erlotinib (150 mg daily))
Not yet recruiting
- Non-small Cell Lung Cancer
- 30 μg OBI-833/100 μg OBI-821
- Erlotinib (150 mg daily)
- (no location specified)
Jun 28, 2022
Uterine Cervical Tumor, Uterine Tumors, Genital Tumors, Female Trial in Seattle (Usual Care, Education, Direct Mail)
Active, not recruiting
- Uterine Cervical Neoplasm
- +13 more
- Usual Care
- +3 more
-
Seattle, WashingtonKaiser Permanente Washington Health Research Institute
Aug 16, 2022
Weight Loss Trial in Chicago (12 Telephone Coaching Sessions, 24 Telephone Coaching Sessions, Report to Primary Care Physician)
Completed
- Weight Loss
- 12 Telephone Coaching Sessions
- +5 more
-
Chicago, IllinoisNorthwestern University
Jan 12, 2023
Breast Cancer Trial in Seattle (Automated message, Opt-out scheduling)
Not yet recruiting
- Breast Cancer
- Automated message
- Opt-out scheduling
-
Seattle, WashingtonVA Puget Sound Health Care System
Apr 5, 2022
Urinary Incontinence, Urinary Urge Incontinence Trial in New Orleans (Vivally® System Wearable, Non-Invasive Neuromodulation
Enrolling by invitation
- Urinary Incontinence
- Urinary Urge Incontinence
- Vivally® System Wearable, Non-Invasive Neuromodulation System, and Mobile Application
-
New Orleans, LouisianaOchsner Medical Center
Oct 10, 2023
Overactive Bladder Trial in Cleveland (At home removal, In office removal)
Not yet recruiting
- Overactive Bladder
- At home removal
- In office removal
-
Cleveland, OhioCleveland Clinic
Mar 23, 2023
Plagiocephaly, Nonsynostotic, Plagiocephaly, Positional, Plagiocephaly Trial (Osteopathic Manipulative Treatment, Standard of
Not yet recruiting
- Plagiocephaly, Nonsynostotic
- +3 more
- Osteopathic Manipulative Treatment
- Standard of Care Repositioning
- (no location specified)
May 8, 2023